Irish section Postgraduate meeting

The impact of fatty acid desaturase genotype on fatty acid status and cardiovascular health in adults

Colette M. O'Neill[1,2]* and Anne-Marie Minihane[1]

[1]*Department of Nutrition and Preventive Medicine, Norwich Medical School, BCRE, University of East Anglia (UEA), James Watson Road, Norwich NR4 7UQ, UK*
[2]*Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Ireland*

The aim of this review was to determine the impact of the fatty acid desaturase (*FADS*) genotype on plasma and tissue concentrations of the long-chain *n*-3 PUFA (LC *n*-3 PUFA), including EPA and DHA, which are associated with the risk of several diet-related chronic diseases, including CVD. In addition to dietary intakes, which are low for many individuals, tissue EPA and DHA are also influenced by the rate of bioconversion from α-linolenic acid (αLNA). Delta 5- and delta-6 desaturase enzymes, encoded for by *FADS1* and *FADS2* genes, are key desaturation enzymes involved in the bioconversion of essential fatty acids (αLNA and linoleic acid (LA)) to longer chained PUFA. In general, carriers of *FADS* minor alleles tend to have higher habitual plasma and tissue levels of LA and αLNA, and lower levels of arachidonic acid, EPA and also to a lesser extent DHA. In conclusion, available research findings suggest that *FADS* minor alleles are also associated with reduced inflammation and CVD risk, and that dietary total fat and fatty acid intake have the potential to modify relationships between *FADS* gene variants and circulating fatty acid levels. However to date, neither the 'size-effects' of *FADS* variants on fatty acid status, nor the functional SNP in *FADS1* and *2* have been identified. Such information could contribute to the refinement and targeting of EPA and DHA recommendations, whereby additional LC *n*-3 PUFA intakes could be recommended for those carrying *FADS* minor alleles.

Eicosapentaenoic acid: EPA: Docosahexaenoic acid: DHA: Arachidonic acid: Long-chain PUFA: Genotype: *FADS*: Cardiovascular: CVD

Plasma and tissue long-chain PUFA (LC-PUFA) concentrations are associated with the risk of several diet-related chronic diseases, including CVD[1–5]. Therefore it is important that the determinants of LC-PUFA metabolism, and concentrations in the circulation and in target tissues are fully understood. *n*-3 fatty acids are PUFA, which contain the first double bond at the third carbon atom from the methyl end of the fatty acid. There are three major long-chain *n*-3 PUFA (LC *n*-3 PUFA) in the human diet and mammalian tissues, namely α-linolenic acid (αLNA), EPA and DHA. Although the most effective means to increase EPA and DHA status is through increased consumption of fish, bioconversion from the essential fatty acid, αLNA, represents a significant source and in particular in non-fish/EPA + DHA supplement consumers who have 57–80 % lower intakes than fish eaters, with EPA and DHA derived from the sequential desaturation and elongation from αLNA[6].

The potential health benefits associated with consumption of EPA and DHA are numerous, with the most studied and accepted being a reduction in CVD risk. As summarised in several systematic reviews and meta-analysis of prospective epidemiological studies and RCT, the ability of LC *n*-3 PUFA to reduce all-cause

---

mortality and cardiovascular mortality has been widely described[1,2,4,7,8]. However, it should be noted that this is not a fully consistent finding, with the heterogeneity in responsiveness as yet not fully understood[9,10]. Consumption of EPA and DHA has also been shown to be associated with many other diseases, for example, autoimmune diseases such as rheumatoid arthritis, cancer, diabetes, respiratory diseases, gastrointestinal diseases, Alzheimer's disease, depression, as well as psychotic disorders, for example schizophrenia[11–14].

The current recommended intakes for EPA plus DHA in the UK are ≥450 mg/d[15]. This recommendation is based largely on the cardiovascular benefits of these fatty acids and can be achieved by consuming two portions of fish per week, one of which should be oily[15]. However, the estimated EPA and DHA consumption in adults in the UK is approximately 270 mg/d for men and 220 mg/d for women, which is far below the recommended minimal intake[6]. Furthermore, mean population intakes are known to be highly skewed, with a large proportion of the population who do not consume fish or an EPA/DHA-containing supplement having a typical EPA plus DHA intake of <50 mg/d[6,16].

n-6 PUFA, including linoleic acid (LA) and arachidonic acid (AA), contain the first double bond at the sixth carbon atom from the methyl end of the fatty acid. LA is an essential fatty acid that is found in vegetable oils and is the most abundant PUFA in the modern Western diet[17]. LA can be metabolised to AA, which in turn, is a precursor of eicosanoids, such as PG, thromboxanes and leukotrienes. These eicoisanoids tend to be pro-inflammatory and therefore may negatively impact on the development of CVD[18].

There is now a large published literature reporting on the impact of individual gene variants on LC-PUFA metabolism and CVD incidence and biomarker profiles. This review will focus on the fatty acid desaturase (*FADS*) genotypes, which are emerging as the most significant common genetic determinants identified to date. Accumulating evidence suggests that the locus may, in the future, be useful in stratification and targeting of LC-PUFA recommendations towards individuals likely to be deficient and responsive.

PUFA bioconversion and the fatty acid desaturase genotype

In addition to dietary intake, tissue EPA and DHA is influenced by the rate of bioconversion from αLNA, which involves multiple desaturation and elongation steps (Fig. 1). The delta-5 and delta-6 desaturase enzymes are the key rate-limiting enzymes in this pathway[19]. The human desaturase complementary DNA were first cloned in 1999 by Cho *et al.*[20,21] and were later identified as *FADS1* and *FADS2* in the human genome[22], located in a cluster on chromosome 11 (*11q12*–13.1). Delta-5 desaturase and delta-6 desaturase are found in many human tissues, but the liver is the site at which they are most highly expressed[20,21]. LA and αLNA are metabolised by the same series of enzymes. EPA and DHA are produced at limited conversion rates of 0·2–6 % for EPA and <0·1 % for DHA in human males and post-menopausal females, with higher rates evident in pre-menopausal females[23]. The more efficient EPA and DHA synthesis in pre-menopausal women is thought to be an evolutionary adaptation, so that younger females have sufficient LC-PUFA to meet the demands of pregnancy and the developing foetus. As will be described, variation across the *FADS* gene region appears to be important in modulating LC-PUFA status. The functional SNP in *FADS1* and *2* have not yet been identified.

Impact of fatty acid desaturase genotype on PUFA status

Using both a candidate gene (Table 1) and a genome wide association study (Table 2) approach, numerous studies have reported associations between variations in the *FADS* locus and desaturase activity and fatty acid status in human subjects. Desaturase activity can be approximated by calculating the product-to-precursor ratio of fatty acids. In 2006, Schaeffer *et al.*[24] analysed eighteen SNP and reconstructed haplotypes in the *FADS1–2* cluster in 727 adults. A five-locus *FADS* haplotype accounted for 27·7, 5·2 and 1·4 % of the variation in AA, EPA and DHA in serum phospholipids, respectively. The minor alleles were associated with higher αLNA and LA and lower gamma-linolenic acid, AA, EPA and n-3 docosapentaenoic acid concentrations, with no significant impact on DHA[24]. More recently, Ameur *et al.* performed genome wide genotyping in 5652 individuals, and targeted resequencing (*n* 960) of the *FADS* region, across five European population cohorts and reported that present-day human subjects have two common *FADS* haplotypes, which are defined by twenty-eight closely linked SNP, one of which was considered to be more efficient in relation to the biosynthesis of LC-PUFA[25]. This *FADS* haplotype was associated with lower levels of LA (borderline significant) and αLNA and higher levels of EPA, gamma-linolenic acid, DHA and AA. Over the last decade, a number of other candidate gene approach studies, as well as genome wide association study, have been conducted and the association between *FADS* SNP/haplotypes and PUFA status, as well as desaturase activities, in plasma have been confirmed and extended to tissue fatty acid composition (Tables 1 and 2). However, information on how factors, including n-3 PUFA intakes, health status and ethnicity, may influence the penetrance of the *FADS* genotype, and in turn the effect size, is relatively unknown. Further research, expanding on the recent research by Wang *et al.*[26], is also required to determine the functional SNP, as well the molecular mechanism(s) responsible for the effect of the *FADS* genotype on EPA and DHA status. Wang *et al.* examined the association between six *FADS* SNP and the lipidomic profile and *FADS1–3* expression in liver samples (*n* 154) and reported all six alleles to be associated with *FADS1* (but not *FADS2* and *3*) gene expression and protein levels, suggesting that the causal variant(s) may be located at *FADS1*[26]. In addition, twenty out of forty-two highly linked SNP

Fig. 1. Synthesis of long-chain PUFA from linoleic (LA) acid and alpha-linolenic acid (αLNA). Both LA (*n*-6) and αLNA (*n*-3) are elongated, desaturated and β-oxidised using the same enzyme system. AA, arachidonic acid.   Q13

were located in the transcription factor-binding sites of the locus. Although it is unclear exactly which SNP is causal and exactly how the SNP influences transcription factor binding and activation of *FADS1*, the findings add considerable credibility to the observations that *FADS* genotypes influence EPA and DHA status.

Impact of fatty acid desaturase genotype on cardiovascular health

The majority of studies to date suggest that *FADS* minor alleles (associated with decreased desaturase activity) are associated with reduced inflammation, total cholesterol, LDL-cholesterol and coronary artery disease risk (Tables 1 and 2)[18,27–31]. In the *Verona Heart Study* (2008), a coronary artery disease incidence of 84 *v.* 66 % was evident in individuals with six to seven *v.* two to three risk alleles and a higher AA/LA ratio was an independent risk factor for coronary artery disease [18]. A potential reason for these findings could involve the high LA intakes in the Western diet, resulting in reduced synthesis of LC *n*-3 PUFA from αLNA[32]. The higher *n*-6

conversion also leads to increased levels of AA, which is a direct precursor of many pro-inflammatory eicosanoids[33,34]. Hester *et al.*[33] recently showed that subjects with the major allele for *FADS* SNP rs174537 had significantly higher levels of pro-inflammatory eicosanoids, LTB4 and 5-HETE, compared with minor allele carriers[33]. However, a few studies have reported contradictory results[35–37] which could be due to the ethnicity of the participants or differences in the *n*-6 to *n*-3 PUFA content of the habitual diet. For example, two studies carried out in a Chinese-Han population reported the frequency of the rs174556 minor allele to be significantly higher in cases of both coronary artery disease and acute coronary syndrome compared with control groups[35,37].

Impact of diet composition on the relationship between the fatty acid desaturase genotype and PUFA and cardiovascular health status

There have been a number of studies that show that diet composition can influence the relationship between *FADS* genotype and plasma fatty acid and lipid status (Table 3). In 2012, Hellstrand *et al.* reported that the

Q12

Table 1. Candidate gene studies: associations between fatty acid desaturase SNP and fatty acid status and cardiovascular health

Study	Subjects	Age (mean (SD or range))	Sex	SNP	Outcomes	Results
Schaeffer et al.[24]	n 727	41·6 (12·3 years, 20–64 years)	Both	rs99780, rs174544, rs174545, rs174546, rs174553, rs174556, rs174561, rs174568, rs174570, rs174583, rs174589, rs174602, rs174620, rs2072114, rs3834458, rs482548, rs526126, rs968567	Fatty acids in serum phospholipids	SNP showed strongest associations with AA ($P < 1·0 \times 10^{-13}$), also with LA, αLNA, EPA ($P < 0·001$)
Baylin et al.[49]	n 1694 MI cases, n 1694 controls	58 (11 years)	Both	rs3834458	PUFA in plasma and adipose tissue. Risk of MI	EPA, LA and AA were significantly decreased in adipose tissue and plasma with increasing copy number of variant alleles ($P < 0·05$ for all). No association with MI
Malerba et al.[50]	n 658	59·7 (11·1 years)	Both	rs174545, rs174556, rs174561, rs174570, rs174583, rs174589, rs174611, rs174627, rs498793, rs1000778, rs2524299, rs3834458, rs17831757	Fatty acids in serum phospholipids and erythrocytes in CVD patients	SNP strongly associated with AA ($P < 1·0 \times 10^{-4}$) in both serum and erythrocytes. Significant associations were also observed for LA and αLNA ($P < 0·05$)
Martinelli et al.[18]	n 266 CAD cases, n 610 controls	59 (10 years)	Both	rs174545, rs174556, rs174561, rs174570, rs174583, rs174589, rs174611, rs174627, rs498793, rs1000778, rs2524299, rs3834458, rs17831757	Serum lipids and other CAD risk factors, including hs-CRP	Increases in hs-CRP concentrations and CAD risk were associated with FADS haplotypes ($P < 0·04$)
Rzehak et al.[51]	n 163 (plasma) + n 535 (erythrocytes)	13–80 years	Both	rs174556, rs174561, rs3834458	Fatty acids in serum phospholipids and erythrocyte membranes	SNP strongly associated with EDA ($P = 7·9 \times 10^{-10}$ for rs3834458) and AA ($P = 1·1 \times 10^{-3}$ for rs174561) in erythrocytes
Mathias et al.[52]	n 224	46·7 (21·2 years)	Both	rs99780, rs174537, rs174545, rs174546, rs174553, rs174556, rs174561, rs174568, rs174570, rs174575, rs174583, rs174611, rs174627, rs498793, rs1000778, rs2524299	Serum n-6 fatty acids	Cluster of SNP in LD (rs174537, rs174545, rs174546, rs174553, rs174556, rs174561, rs174568, and rs99780) associated with AA ($P = 5·8 \times 10^{-7}$–$1·7 \times 10^{-8}$) among other PUFA. FADS1 activity ratio associated with the −6 series ($P = 2·11 \times 10^{-13}$–$1·8 \times 10^{-20}$)
Zietemann et al.[53]	n 2066	35–65 years in women, 40–65 years in men	Both	rs174546	n-6 PUFA composition in erythrocyte membranes	rs174546 related to estimated D6D activity (r^2 0·052) and D5D activity (r^2 0·231). Genetic effect on D5D activity and DGLA modified by the dietary n-6 : n-3-ratio (P-values for interaction: 0·008 and 0·002)
Merino et al.[54]	Caucasian: n 78, Asian: n 69	20–29 years	Both	rs174547, rs174570, rs174576, rs174579, rs174593, rs174602, rs174611, rs174627, rs412334, rs482548, rs498793, rs526126, rs695867, rs968567, rs17831757, rs2072114, rs2845573	Plasma fatty acids	rs174547 associated with AA:LA in both Caucasians ($P = 4·0 \times 10^{-8}$) and Asians ($P = 5·0 \times 10^{-5}$). Although the minor allele for this SNP differed between Caucasians (T) and Asians (C), carriers of the C allele had a lower desaturase activity than carriers of the T allele in both groups
Qin et al.[35]	n 199 CAD cases, n 192 controls	62·5 (20·4 years)	Both	rs174556, rs174617	Distribution of FADS genotype in CAD cases and controls	The frequency of rs174556 minor allele was significantly higher in the case than control group ($P = 0·030$)

Lu et al.[36]	n 1860	47·5 (7·9 years, 45–85 years)	Both	rs17454	Distribution of FADS genotype and PUFA in incident CHD cases and controls at follow-up	rs174547 major allele was associated with increased plasma levels of AA, EPA and DHA and increased desaturase activity, but not with CHD risk. High baseline desaturase activity was associated with reduced CHD risk (P for trend = 0·02), especially among those carrying the major allele (HR (95 % CI) = 0·35 (0·15, 0·81) for comparing the extreme quintiles)
Freemantle et al.[55]	n 61	18–58 years	Male	rs174546, rs174548, rs174549, rs174555	Fatty acid composition in cortical brain tissue	Association of the minor haplotype with estimated fatty acid desaturase activity (P = 0·04). No significant association of the impact of variants on expression and alternative transcripts of FADS1 and FADS2. Significant interaction between haplotype and age on LA and AA
Song et al.[37]	n 249 ACS cases, n 240 controls	62·5 (20·4 years)	Both	rs174556, rs174617	Distribution of FADS genotype in ACS cases and controls	The frequency of rs174556 minor allele was higher in the case group than the control group (P = 0·036)
Li et al.[28]	n 505 CAD cases, n 510 controls	33–85 years	Both	rs174460, rs174537, rs174550, rs174611, rs174616	Plasma fatty acids	D6D activity (AA/LA), was higher in CAD patients (P < 0·001). rs174537 minor allele associated with lower risk of CAD (OR 0·743, 95 % CI (0·624, 0·884), P = 0·001). Carriers of the rs174460 minor allele were associated with a higher risk of CAD (OR 1·357, 95 % CI (1·106, 1·665), P = 0·003)
Hong et al.[56]	n 122	35–59 years	Male	rs1000778, rs174537, rs174575, rs2727270	Serum phospholipid PUFA, oxidative stress markers over 3 years	rs174537 showed strongest association; minor allele did not show the age-associated increases in AA (P = 0·022) and D5D activity (P = 0·007) seen with the rs174537 major genotype
Roke et al.[57]	n 878	20–29 years	Both	Nineteen SNP were genotyped in all subjects and six (rs174579, rs174593, rs174626, rs526126, rs968567 and rs17831757) were further analysed	Plasma fatty acids and hs-CRP	All six SNP that were further analysed significantly associated with AA levels and desaturase indices. Inverse association between FADS1 desaturase index and hs-CRP (P = 4·41 × 10^{-6})
Hester et al.[33]	n 30	21–65 years	Female	rs174537	Serum fatty acids. Eicosanoids: leukotriene, HETE, PG and thromboxane biosynthesis in stimulated whole blood	Associations between rs174537 and desaturase activity (P = 0·035), leukotriene B$_4$ (P = 0·001), and 5-HETE (P = 0·048)
Wang et al.[26]	n 154	No data	Both	rs1535, rs102275, rs174537, rs174546, rs174556, rs174576	Hepatic lipid composition	Minor alleles associated with the accumulation of VLCFAs, increased ratios between the more saturated and relatively less saturated forms of VLCFA and increased total hepatic fat content (P < 0·05)
Horiguchi et al.[58]	n 124	≥65 years	Both	rs17454	Erythrocyte membrane and plasma phospholipid LCPUFA	rs174547 minor allele associated with lower AA and higher LA levels in erythrocyte membrane and plasma phospholipid (P < 0·0001)

Table 1. (Cont.)

Study	Subjects	Age (mean (SD or range))	Sex	SNP	Outcomes	Results
Vaittinen et al.[59]	n 89 at baseline and n 64 at follow-up	46·3 (8·8 years)	Both	rs174547, rs174616	Surgery-induced weight loss, Adipose tissue fatty acids and inflammation (IL-1 and NFKB)	SNP associated with estimated desaturase activity at baseline and follow-up ($P < 0.006$) and adipose tissue inflammation at follow-up ($P < 0.03$)
Li et al.[45]	n 872	59·3 (10·8 years)	Both	rs174450, rs174460, rs174537, rs174616	Plasma fatty acid and lipid composition T2D, CAD, both T2D and CAD, compared with healthy controls	T2D patients with rs174537 major allele were at risk of developing T2D and CAD (OR 1·763; 95 % CI 1·143, 2·718; $P = 0.010$), with elevated plasma LDL-C, AA and desaturase activity
Schuchardt et al.[60]	n 111	69 (7·6, 50–80 years)	Both	rs1535, rs174546, rs174548, rs174449, rs174455, rs174574, rs174575, rs174576, rs174578, rs174579, rs526126, rs3834458	Erythrocyte membrane LC-PUFA in patients with mild cognitive impairment	Minor allele carriers of several SNP had higher LA and αLNA, lower AA levels in erythrocyte membranes compared with the major allele carriers ($P < 0.001$)

AA, arachidonic acid; LA, linoleic acid; αLNA, alpha-linolenic acid, MI, myocardial infarction, CAD, coronary artery disease; hs-CRP, high sensitivity C-reactive protein; EDA, eicosadienoic acid; LD, linkage disequilibrium; D6D, delta-6-desaturase; D5D, delta-5-desaturase; DGLA, dihomo-gamma-linolenic acid; HR, hazard ratio; ACS, acute coronary syndrome; VLCFA, very long-chained fatty acids; T2D, type 2 diabetes.

Table 2. Genome wide association studies: associations between fatty acid desaturase SNP and fatty acid status and cardiovascular health

Study	Subjects	Age (mean (SD or range))	Sex	Outcomes	Results
Gieger et al.[61]	n 284	35–79 years	Male	363 metabolites in serum	Association between rs174548 and PC C36:4 ($P = 4.52 \times 10^{-8}$) and D5D product–substrate ratio ($P = 2.4 \times 10^{-22}$)
Tanaka et al.[62]	n 1210 + 1076 (replication)	12–102 years	Both	Fatty acids in plasma and blood lipids	Associations between rs174537 and AA ($P = 5.95 \times 10^{-46}$), TC ($P = 2.7 \times 10^{-2}$), LDL-C ($P = 1.1 \times 10^{-2}$)
Aulchenko et al.[29]	n 17 797–22 562	18–104	Both	Blood lipid parameters	Associations between rs174570 and TC ($P = 1.5 \times 10^{-10}$) and LDL-C ($P = 4.4 \times 10^{-13}$)
Sabatti et al.[31]	n 4763	31 years	Both	Metabolic traits (TAG, cholesterol, etc.)	Associations between rs174546, rs102275, rs174537, rs174556, rs1535 and LDL-C ($P = 1.3$–3.7×10^{-7})
Kathiresan et al.[63]	n 19 840 + 22 562 (replication)	All ages	Both	Blood lipid parameters	Associations between rs174547 and TAG ($P = 2.0 \times 10^{-14}$) and HDL-C ($P = 2.0 \times 10^{-12}$)
Ameur et al.[25]	Genome-wide genotyping (n 5652) and targeted resequencing (n 960) five European population cohorts	All ages	Both	Fatty acid in blood phospholipid	FADS haplotype associated with lower levels of LA ($P = 0.052$) and αLNA ($P = 0.024$) and higher levels of EPA ($P = 1.1 \times 10^{-12}$), GLA ($P = 1.3 \times 10^{-18}$), DHA ($P = 8.3 \times 10^{-5}$) and AA ($P = 5.2 \times 10^{-18}$)
Guan et al.[64]	n 8631	60·3 years	Both	Plasma n-6 PUFA composition	FADS cluster associated with LA, AA, GLA, DGLA and adrenic acid
Mozaffarian et al.[65]	n 8013	45·8 (3·4)–75·0 (5·1 years)	Both	Phospholipid trans-fatty acids	Thirty-one FADS SNP associated with cis/trans-LA. No significant association was identified for other TFA

PC, phosphatidylcholine; D5D, delta-5-desaturase; AA, arachidonic acid; TC, total cholesterol; LA, linoleic acid; αLNA, alpha-linolenic acid; GLA, gamma-linolenic acid; DGLA, dihomo-gamma-linolenic acid; TFA, trans-fatty acid.

Table 3. Diet–gene interactions: impact of dietary intakes/interventions on associations between fatty acid desaturase genotype and fatty acid status and cardiovascular health

Study	Subjects	Age (mean (SD or range))	Sex	SNP	Intakes/intervention	Outcomes	Results
Lu et al.[66]	n 3575	46·7 (9·8 years)	Both	rs174546, rs174570, rs482548	Dietary intakes of n-3 and n-6 PUFA	Plasma TC, HDL-C, and non-HDL-C	rs174546 major allele associated with high TC and non-HDL-C in high n-3 PUFA group ($\geqslant$0·51 % of total energy; $P = 0·006$ and 0·047, respectively) and with high HDL-C in the group with a high intake of n-6 PUFA ($\geqslant$5·26 % of total energy, $P = 0·004$)
Hellstrand et al.[38]	n 4635	45–68 years	Both	rs174547	PUFA intakes	Blood lipids concentrations	rs174547 minor allele associated with lower LDL-C ($P = 0·03$) and with lower LDL-C in the lowest tertile of LC n-3 PUFA intakes ($P < 0·001$). An interaction was observed between rs174547 and the ratio of αLNA and LA intakes on HDL-C ($P = 0·03$)
Cormier et al.[67]	n 208	18–50 years	Both	rs174448, rs174456, rs174546, rs174570, rs174579, rs174602, rs174611, rs174616, rs174627, rs482548, rs498793, rs968567, rs2072114, rs2845573, rs7394871, rs7935946, rs7942717, rs12807005, rs74823126	3 g/d supplement of n-3 PUFA for 6 weeks	Blood lipid concentrations	SNP rs174546 was associated ($P = 0·02$) with TAG, pre- and post-supplementation; no significant genotype by supplementation interaction was observed
Gillingham et al.[40]	n 36	18–65 years	Both	rs174537, rs174545, rs174561, rs174583, rs953413	Three isoenergetic diets with either 20·6, 2·4 or 1·3 g αLNA/d for 4 weeks	Plasma fatty acids and ^{13}C-labelled αLNA (at 0, 24 and 48 h) in hyper-lipidaemic subjects	20·6 g αLNA/d increased ($P < 0·001$) plasma αLNA, EPA and DPA. At 24 and 48 h, ^{13}C-labelled αLNA recovered as plasma ^{13}C-EPA and ^{13}C-DPA were lower ($P < 0·001$) after the 20·6 g αLNA/d diet. Minor allele homozygotes of rs174545, rs174583, rs174561 and rs174537 had lower ($P < 0·05$) plasma EPA, AA and desaturase ratio compositions, and lower ($P < 0·05$) plasma ^{13}C-EPA enrichment at 24 and 48 h in comparison with carriers of the major allele after all diets
Al-Hilal et al.[68]	n 310	45–70 years	Both	rs174537, rs174561, rs3834458	Supplementation with EPA and DHA at three doses (0.45, 0.9 and 1.8 g/d)	LC-PUFA and desaturase activities estimated in plasma and RBC	Minor alleles associated with decreased desaturase activities of ($5·84 \times 10^{-19} \leqslant P \leqslant 4·2 \times 10^{-7}$). Interaction of rs174537 genotype with treatment was a determinant of desaturase activity estimated in plasma ($P = 0·05$)

Table 3. (*Cont*.)

Study	Subjects	Age (mean (SD or range))	Sex	SNP	Intakes/intervention	Outcomes	Results
Porenta et al.[42]	n108	53·0 (11·6 years)	Both	rs174537, rs174556, rs174561, rs3834458	Mediterranean diet intervention for 6 months	Fatty acids in serum and colonic mucosa in those at increased risk of colon cancer	No diet by genotype effect of the intervention on serum fatty acid status. Significant diet by genotype interaction for AA in the colon; subjects with all major alleles for *FADS* SNP and were following the Mediterranean diet had 16 % lower AA compared with control subjects
Roke & Mutch[69]	n 12	18–25 years	Male	rs174537, rs174576	12-week fish-oil supplementation, providing 1200 mg EPA and 600 mg DHA/d	FA levels in serum and RBC. TAG, TC,LDL-C, HDL-C, glucose, insulin, HbA1c and hs-CRP	Minor allele carriers for both SNP had greater increases in RBC EPA following supplementation ($P < 0·05$)
Hellstrand et al.[39]	n 24 032	44–74 years	Both	rs174546	PUFA intakes	CVD incidence	αLNA:LA intake ratio inversely associated with CVD risk minor allele (HR for quintile 5 *v*. quintile 1 = 0·72; 95 % CI 0·50, 1·04; P-trend = 0·049). Interaction between αLNA and rs174546 and ischaemic stroke incidence ($P = 0·03$); αLNA was inversely associated with ischaemic stroke only among minor allele carriers (HR for quintile 5 *v*. quintile 1 = 0·50; 95 % CI 0·27, 0·94; P-trend = 0·02)
Cormier et al.[44]	n 208	18–50 years	Both	rs174448, rs174456, rs174546, rs174570, rs174579, rs174602, rs174611, rs174616, rs174627, rs482548, rs498793, rs968567, rs2072114, rs2845573, rs7394871, rs7935946, rs7942717, rs12807005, rs74823126	3 g/d supplement of n-3 PUFA for 6 weeks	Estimated desaturase activities	Desaturase indexes were significantly different following the 6-week n-3 supplementation. The index of D5D activity increased by 25·7 (28·8 %) ($P < 0·0001$), whereas the index of D6D activity decreased by 17·7 (18·2 %) ($P < 0·0001$) post supplementation

TC, total cholesterol; LC, long chained; αLNA, alpha-linolenic acid; LA, linoleic acid; DPA, docosapentaenoic acid; hs-CRP, high sensitivity C-reactive protein; RBC, red blood cells; HR, hazard ratio; D5D, delta-5-desaturase; D6D, delta-6-desaturase; LDL-C, LDL-cholesterol.

FADS rs174547 minor allele was associated with lower LDL-cholesterol among individuals in the lowest tertile of LC *n*-3 PUFA intakes[38]. A significant interaction between rs174547 and the ratio of αLNA and LA intakes on HDL-C was also observed[38]. More recently, a 14-year follow-up in 24 032 participants reported that the αLNA-to-LA intake ratio was inversely associated with CVD risk only among participants homozygous for the rs174547 minor allele[39]. αLNA intakes were also inversely associated with ischaemic stroke in this genotype group. In addition to observational analysis, the impact of *FADS* variants on response to LC-PUFA supplementation has also been examined. Gillingham *et al.* carried out a randomised crossover trial carried out in thirty-six hyperlipidemic subjects in which three diets (enriched with flaxseed oil or high-oleic acid canola oil compared with a typical Western diet) were consumed for 4 weeks and five *FADS* SNP were analysed[40]. Subjects with minor allele variants (rs174545, rs174583, rs174561, rs174537) had decreased desaturase activity, but an increase in αLNA intakes resulted in greater increases in plasma EPA than in major allele homozygotes consuming αLNA intakes typical of a Western diet[40]. Cormier *et al.* conducted a study in 208 subjects examining the impact of fish-oil supplementation (1·9–2·2 g/d EPA and 1·1 g/d DHA) for 6 weeks and nineteen *FADS* SNP on plasma TAG and reported that rs174546 was associated with TAG, but no significant genotype by supplementation interaction was observed[41]. In terms of whole-diet interventions, one study to date has examined the interaction of *FADS* genotype and the Mediterranean diet on serum and colonic fatty acid profiles[42]. In a 6-month intervention (*n* 108) and genotyping for four *FADS* SNP, a significant diet by genotype interaction for AA concentrations in the colon was observed; subjects with *FADS* major alleles following the Mediterranean diet had 18 % lower AA concentrations than subjects on the control diet (healthy eating diet)[42]. There were no significant diets by genotype interactions for other colonic or serum fatty acids. Overall, it is clear that further research is necessary to determine the potential of the diet, particularly dietary fatty acids, to modify the relationship between the *FADS* genotype and fatty acid status. An investigation of diet composition × *FADS* genotype × fatty acid status represents a secondary objective of the recently completed NU-AGE intervention.

NU-AGE: a focus on older adults

The NU-AGE study investigated the impact of a whole-diet intervention on markers of chronic inflammation in older adults (aged 65–79 years)[43]. The NU-AGE recommendations for the consumption of oily fish, as well as the provision of an αLNA-rich spread, aimed to increase total *n*-3 PUFA intakes and the dietary *n*-6 : *n*-3 PUFA ratio of study participants. As previously discussed, although a small number of dietary interventions have been shown to modify the relationship

between the *FADS* genotype and PUFA status[40,42,44]; none have examined the impact of a 1-year whole-diet (including significant fatty acid manipulation) intervention in older adults, a group who are likely to be in a higher state of chronic inflammation and CVD risk relative to healthy general adult population. Therefore, we aim to examine whether the NU-AGE diet could influence the relationship between the *FADS* genotype and plasma PUFA status in our study population. Specifically, we wish to establish if the NU-AGE diet can overcome any identified negative impacts of *FADS* minor alleles on EPA and DHA status, as well as the potential negative effect that the major allele has on AA status. We will also examine the interactive impact of diet and *FADS* genotype on CVD risk biomarkers, including inflammatory and plasma lipid status and measures of vascular function and arterial stiffness[18,27,28].

Summary and conclusion

Current estimates indicate that for most countries, average population intakes of EPA and DHA are 0·2 g/d, and < 0·05 g/d in non-fish consumers[16]. In this latter large population subgroup, the efficacy of endogenous synthesis from αLNA determines the tissue EPA and DHA status. A comprehensive understanding of the determinants of the regulation of the desaturation and elongation pathway is lacking. Although common *FADS* variants have been consistently associated with LC-PUFA status, the exact size of the effect is relatively unquantified and the *FADS* functional gene variant(s) has not been identified. A recent study by Li *et al.*[28] (described in Table 1) reported a difference of 8·3 % in plasma EPA and DHA combined between those homozygous for the major allele and those homozygous for the minor allele of the rs174537 *FADS* genotype[45]. This is clinically significant as previous research, which showed that EPA and DHA status was associated with sudden cardiac death in US males, reported 9·0 % lower blood EPA and DHA concentrations in the sudden death group compared with controls[46]. Modest dietary intakes of EPA and DHA could overcome this genotype effect; supplementation of 300 mg EPA and DHA or 90 g of salmon per week has been shown to increase combined plasma EPA plus DHA by about 30 %[47,48]. The mechanistic basis of the relationship between the *FADS* genotype and LC *n*-3 PUFA interactions are also poorly understood. The impact of *FADS* genotype on PUFA status should be carefully considered when using plasma and tissue EPA and DHA concentrations as biomarkers of dietary EPA and DHA exposure in RCT and epidemiological studies, with a greater contribution of endogenously synthesised EPA, and to a lesser extent DHA, to the total pool likely in *FADS* major allele carriers. Furthermore, *FADS* genotype could contribute to future stratification and targeting of dietary advice with additional EPA and DHA intakes recommended for those carrying the *FADS* minor allele.

References

1. Bucher HC, Hengstler P, Schindler C *et al.* (2002) *N*-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. *Am J Med* **112**, 298–304.
2. Mente A, de Koning L, Shannon HS *et al.* (2009) A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med* **169**, 659–669.
3. Wang Q, Liang X, Wang L *et al.* (2012) Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. *Atherosclerosis* **221**, 536–543.
4. Wang C, Harris WS, Chung M *et al.* (2006) *n*-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr* **84**, 5–17.
5. Dacks PA, Shineman DW & Fillit HM (2013) Current evidence for the clinical use of long-chain polyunsaturated *n*-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease. *J Nutr Health Aging* **17**, 240–251.
6. Welch AA, Shakya-Shrestha S, Lentjes MA *et al.* (2010) Dietary intake and status of *n*-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the precursor-product ratio of α-linolenic acid to long-chain *n*-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort. *Am J Clin Nutr* **92**, 1040–1051.
7. León H, Shibata MC, Sivakumaran S *et al.* (2008) Effect of fish oil on arrhythmias and mortality: systematic review. *BMJ* **337**.
8. Studer M, Briel M, Leimenstoll B *et al.* (2005) Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med* **165**, 725–730.
9. Rizos EC, Ntzani EE, Bika E *et al.* (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA* **308**, 1024–1033.
10. Kwak SM, Myung SK, Lee YJ *et al.* (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Arch Intern Med* **172**, 686–694.
11. Fetterman JW Jr & Zdanowicz MM (2009) Therapeutic potential of *n*-3 polyunsaturated fatty acids in disease. *Am J Health Syst Pharm* **66**, 1169–1179.
12. Janssen CI & Kiliaan AJ (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. *Prog Lipid Res* **53**, 1–17.
13. Chen C, Yu X & Shao S (2015) Effects of omega-3 fatty acid supplementation on glucose control and lipid levels in Type 2 Diabetes: a meta-analysis. *PLoS ONE* **10**, e0139565.
14. Jump DB, Depner CM, Tripathy S *et al.* (2015) Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. *Adv Nutr* **6**, 694–702.
15. Scientific Advisory Committee on Nutrition. Committee on Toxicity of Chemicals in Food (2004) Advice on Fish Consumption: Benefits and Risks.
16. Minihane AM (2013) Fish oil omega-3 fatty acids and cardio-metabolic health, alone or with statins. *Eur J Clin Nutr* **67**, 536–540.
17. Chilton FH, Murphy RC, Wilson BA *et al.* (2014) Diet-gene interactions and PUFA metabolism: a potential contributor to health disparities and human diseases. *Nutrients* **6**, 1993–2022.
18. Martinelli N, Girelli D, Malerba G *et al.* (2008) FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. *Eur J Clin Nutr* **88**, 941–949.
19. Sprecher H (1981) Biochemistry of essential fatty acids. *Prog Lipid Res* **20**, 13–22.
20. Cho HP, Nakamura M & Clarke SD (1999) Cloning, expression, and fatty acid regulation of the human delta-5 desaturase. *J Biol Chem* **274**, 37335–37339.
21. Cho HP, Nakamura MT & Clarke SD (1999) Cloning, expression, and nutritional regulation of the mammalian delta-6 desaturase. *J Biol Chem* **274**, 471–477.
22. Marquardt A, Stohr H, White K *et al.* (2000) cDNA cloning, genomic structure, and chromosomal localization of three members of the human fatty acid desaturase family. *Genomics* **66**, 175–183.
23. Burdge GC (2006) Metabolism of α-linolenic acid in humans. *Prostaglandins Leukot Essent Fatty Acids* **75**, 161–168.
24. Schaeffer L, Gohlke H, Muller M *et al.* (2006) Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum Mol Genet* **15**, 1745–1756.
25. Ameur A, Enroth S, Johansson A *et al.* (2012) Genetic adaptation of fatty-acid metabolism: a human-specific haplotype increasing the biosynthesis of long-chain omega-3 and omega-6 fatty acids. *Am J Hum Genet* **90**, 809–820.
26. Wang L, Athinarayanan S, Jiang G *et al.* (2015) Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition. *Hepatology* **61**, 119–128.
27. Kwak JH, Paik JK, Kim OY *et al.* (2011) FADS gene polymorphisms in Koreans: association with omega6 polyunsaturated fatty acids in serum phospholipids, lipid peroxides, and coronary artery disease. *Atherosclerosis* **214**, 94–100.
28. Li S-W, Lin K, Ma P *et al.* (2013) FADS gene polymorphisms confer the risk of coronary artery disease in a Chinese

Han population through the altered desaturase activities: based on high-resolution melting analysis. *PLoS ONE* **8**, e55869.

29. Aulchenko YS, Ripatti S, Lindqvist I *et al.* (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat genet* **41**, 47–55.

30. Standl M, Lattka E, Stach B *et al.* (2012) FADS1 FADS2 gene cluster, PUFA intake and blood lipids in children: results from the GINIplus and LISAplus studies. *PLoS ONE* **7**, e37780.

31. Sabatti C, Service SK, Hartikainen A-L *et al.* (2009) Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. *Nat Genet* **41**, 35–46.

32. Blasbalg TL, Hibbeln JR, Ramsden CE *et al.* (2011) Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. *Am J Clin Nutr* **93**, 950–962.

33. Hester AG, Murphy RC, Uhlson CJ *et al.* (2014) Relationship between a common variant in the fatty acid desaturase (FADS) cluster and eicosanoid generation in humans. *J Biol Chem* **289**, 22482–22489.

34. Mathias R, Pani V & Chilton F (2014) Genetic variants in the FADS gene: implications for dietary recommendations for fatty acid intake. *Curr Nutr Rep* **3**, 139–148.

35. Qin L, Sun L, Ye L *et al.* (2011) A case–control study between the gene polymorphisms of polyunsaturated fatty acids metabolic rate-limiting enzymes and coronary artery disease in a Chinese Han population. *Prostaglandins Leukot Essent Fatty Acids* **85**, 329–333.

36. Lu Y, Vaarhorst A, Merry AH *et al.* (2012) Markers of endogenous desaturase activity and risk of coronary heart disease in the CAREMA cohort study. *PLoS ONE* **7**, e41681.

37. Song Z, Cao H, Qin L *et al.* (2013) A case–control study between gene polymorphisms of polyunsaturated fatty acid metabolic rate-limiting enzymes and acute coronary syndrome in Chinese Han population. *BioMed Res Int* **2013**, 928178.

38. Hellstrand S, Sonestedt E, Ericson U *et al.* (2012) Intake levels of dietary long-chain PUFAs modify the association between genetic variation in FADS and LDL-C. *J Lipid Res* **53**, 1183–1189.

39. Hellstrand S, Ericson U, Gullberg B *et al.* (2014) Genetic variation in FADS1 has little effect on the association between dietary PUFA intake and cardiovascular disease. *J Nutr* **144**, 1356–1363.

40. Gillingham LG, Harding SV, Rideout TC *et al.* (2013) Dietary oils and FADS1-FADS2 genetic variants modulate [13C]α-linolenic acid metabolism and plasma fatty acid composition. *Am J Clin Nutr* **97**, 195–207.

41. Cormier H, Rudkowska I, Paradis AM *et al.* (2012) Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an *n*-3 PUFA supplementation. *Nutrients* **4**, 1026–1041.

42. Porenta SR, Ko Y-A, Gruber SB *et al.* (2013) Interaction of fatty acid genotype and diet on changes in colonic fatty acids in a Mediterranean diet intervention study. *Cancer Prev Res* **6**. doi. 10.1158/940-6207.

43. Berendsen A, Santoro A, Pini E *et al.* (2013) A parallel randomized trial on the effect of a healthful diet on inflammageing and its consequences in European elderly people: design of the NU-AGE dietary intervention study. *Mech Ageing Dev* **134**, 523–530.

44. Cormier H, Rudkowska I, Lemieux S *et al.* (2014) Effects of FADS and ELOVL polymorphisms on indexes of desaturase and elongase activities: results from a pre-post fish oil supplementation. *Genes Nutr* **9**, 437.

45. Li S-W, Wang J, Yang Y *et al.* (2016) Polymorphisms in FADS1 and FADS2 alter plasma fatty acids and desaturase levels in type 2 diabetic patients with coronary artery disease. *J Transl Med* **14**, 1–9.

46. Albert CM, Ma J, Rifai N *et al.* (2002) Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation* **105**, 2595–2599.

47. Flock MR, Skulas-Ray AC, Harris WS *et al.* (2013) Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose–response randomized controlled trial. *J Am Heart Assoc* **2**. **Q10**

48. Raatz SK, Rosenberger TA, Johnson LK *et al.* (2013) Dose-dependent consumption of farmed Atlantic salmon (*Salmo salar*) increases plasma phospholipid *n*-3 fatty acids differentially. *J Acad Nutr Diet* **113**, 282–287.

49. Baylin A, Ruiz-Narvaez E, Kraft P *et al.* (2007) α-Linolenic acid, Δ6-desaturase gene polymorphism, and the risk of non-fatal myocardial infarction. *Am J Clin Nutr* **85**, 554–560.

50. Malerba G, Schaeffer L, Xumerle L *et al.* (2008) SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. *Lipids* **43**, 289–299.

51. Rzehak P, Heinrich J, Klopp N *et al.* (2009) Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes. *Br J Nutr* **101**, 20–26.

52. Mathias RA, Vergara C, Gao L *et al.* (2010) FADS genetic variants and omega-6 polyunsaturated fatty acid metabolism in a homogeneous island population. *J Lipid Res* **51**, 2766–2774.

53. Zietemann V, Kröger J, Enzenbach C *et al.* (2010) Genetic variation of the FADS1 FADS2 gene cluster and *n*-6 PUFA composition in erythrocyte membranes in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. *Br J Nutr* **104**, 1748–1759.

54. Merino DM, Johnston H, Clarke S *et al.* (2011) Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults. *Mol Genet Metab* **103**, 171–178.

55. Freemantle E, Lalovic A, Mechawar N *et al.* (2012) Age and haplotype variations within FADS1 interact and associate with alterations in fatty acid composition in human male cortical brain tissue. *PLoS ONE* **7**, e42696.

56. Hong SH, Kwak JH, Paik JK *et al.* (2013) Association of polymorphisms in FADS gene with age-related changes in serum phospholipid polyunsaturated fatty acids and oxidative stress markers in middle-aged nonobese men. *Clin Interv Aging* **8**, 585–596.

57. Roke K, Ralston JC, Abdelmagid S *et al.* (2013) Variation in the FADS1/2 gene cluster alters plasma *n*-6 PUFA and is weakly associated with hsCRP levels in healthy young adults. *Prostaglandins Leukot Essent Fatty Acids* **89**, 257–263.

58. Horiguchi S, Nakayama K, Iwamoto S *et al.* (2016) Associations between a fatty acid desaturase gene polymorphism and blood arachidonic acid compositions in Japanese elderly. *Prostaglandins Leukot Essent Fatty Acids* **105**, 9–14.

59. Vaittinen M, Walle P, Kuosmanen E *et al.* (2016) FADS2 genotype regulates delta-6 desaturase activity and inflammation in human adipose tissue. *J Lipid Res* **57**, 56–65.

60. Schuchardt JP, Köbe T, Witte V *et al.* (2016) Genetic variants of the FADS gene cluster are associated with erythrocyte membrane LC PUFA levels in patients with mild cognitive impairment. *J Nutr Health Aging* 1–10. **Q11**

61. Gieger C, Geistlinger L, Altmaier E *et al.* (2008) genetics meets metabolomics: a genome-wide association study of

metabolite profiles in human serum. *PLoS Genet* **4**, e1000282.

62. Tanaka T, Shen J, Abecasis GR *et al.* (2009) Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS Genet* **5**, e1000338.

63. Kathiresan S, Willer CJ, Peloso GM *et al.* (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet* **41**, 56–65.

64. Guan W, Steffen BT, Lemaitre RN *et al.* (2014) Genome-wide association study of plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology consortium. *Circ Cardiovasc Genet* **7**, 321–331.

65. Mozaffarian D, Kabagambe EK, Johnson CO *et al.* (2015) Genetic loci associated with circulating phospholipid trans fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. *Am J Clin Nutr* **101**, 398–406.

66. Lu Y, Feskens EJ, Dolle ME *et al.* (2010) Dietary *n*-3 and *n*-6 polyunsaturated fatty acid intake interacts with FADS1 genetic variation to affect total and HDL-cholesterol concentrations in the Doetinchem Cohort Study. *Am J Clin Nutr* **92**, 258–265.

67. Cormier H, Rudkowska I, Paradis A-M *et al.* (2012) Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an *n*-3 PUFA supplementation. *Nutrients* **4**, 1026–1041.

68. Al-Hilal M, Alsaleh A, Maniou Z *et al.* (2013) Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. *J Lipid Res* **54**, 542–551.

69. Roke K & Mutch DM (2014) The role of FADS1/2 polymorphisms on cardiometabolic markers and fatty acid profiles in young adults consuming fish oil supplements. *Nutrients* **6**, 2290–2304.